DURHAM, N.C., April 13, 2016 – Arcato Laboratories, developer of OraWaxTM, a revolutionary new treatment for the discomfort caused by orthodontic braces, has been invited to present at the Landmark Venture Forum, which will be held April 21, 2016 at the Greenwich Hyatt Regency in Old Greenwich, Connecticut.
“In the United States alone, 4 million people wear braces and most of them agree that braces are painful,” said Christopher Meldrum, President & CEO of Arcato Laboratories. “Arcato’s solution is OraWax™, a patented time-release formulation combining wax, benzocaine, and special polymers,” he added.
“Based upon the market analysis conducted by the company, the OraWax™ product has an estimated market of about $400 million per year,” Meldrum stated.
Arcato is currently raising $1 million in a Series B round of financing, to complete 510(k) FDA regulatory clearance for OraWax™, and launch the product in the United States.
About Arcato Laboratories
Arcato Laboratories, a leader in the sustained release of anesthetics, is commercializing proprietary products to serve specialty oral healthcare practitioners, such as orthodontists and oral surgeons. Arcato’s first product, a medical device named OraWax™, targets orthodontists and their patients as the first effective treatment for oral discomfort caused by orthodontic appliances (braces). For more information on investing, please visit our Investor Relations Page.